UK’s CGT, Australian CTM CRC Sign Agreement
News May 24, 2016
The Cell and Gene Therapy Catapult (CGT) and the CRC for Cell Therapy Manufacturing (CTM CRC) have announced a project to test at scale CTM CRC’s patented scaffold technology. The technology is designed for T-cell stimulation and expansion and the testing by CGT will provide independent supporting data for ultimate commercial scale up of this technology.
The consortium will then investigate opportunities to apply this technology to commercial scale cell expansion systems. If successful, this novel scaffold technology will provide a platform for generating large numbers of activated T-cells for cell-based immunotherapies. This platform technology could be applied to therapies for a range of clinical conditions such as cancer and autoimmune diseases.
Keith Thompson, CEO, the Cell and Gene Therapy Catapult said: “The issue of scale in cell and gene therapies, is one of the toughest challenges the industry faces. We need to have the ability to grow cells reliably and cost effectively at scale in order to get these promising therapies to patients. This project is one of several where we are looking at adapting technologies to achieve that scale up. Collaborating with CTM CRC shows that it’s an international effort that’s needed to ensure we address the barriers in the industry.”
Developed across three of CTM’s participant organisations, The Women’s and Children’s Hospital, The University of South Australia and Queensland University of Technology, the technology is competitive with the current gold standard in T-cell stimulation and expansion at the laboratory scale. The consortium will use CGT’s experience in, and access to scale up processes for cell expansion.
Sherry Kothari, CEO, the CRC for Cell Therapy Manufacturing said: “We have a strong focus on addressing the cost of manufacture through intervention with smart surfaces and materials. This project is an example of how simple and cost effective strategies are being applied to optimise and improve existing cell expansion processes. This collaboration with CGT provides the perfect vehicle for evaluating the translation and scale up of promising technologies. International collaborations such as these enable rapid adoption by, and value-add to a global industry, ultimately giving patients with currently untreatable medical conditions a better chance of access to life-saving therapies.”
This project is being carried out under an extension of the Memorandum of Understanding, signed between the two organisations in 2015 and will further develop the partnership between the two organisations.
Understanding of Platelet Production Challenged By State of the Art ImagingNews
Correlative light-electron microscopy is being used to increase our knowledge of how platelets are made in the body and the results are challenging previously held understandings.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE